Efficacy of olipudase alfa-rpcp
Olipudase alfa-rpcp is an enzyme replacement therapy drug specifically used to treat acid sphingomyelinase deficiency (ASMD), commonly known as Niemann-Pick disease type B. This rare genetic metabolic disease causes abnormal accumulation of lipids due to the lack of normal-functioning acid sphingomyelinase in the patient's body, affecting the functions of the liver, spleen, lungs and other organs, and is life-threatening in severe cases. Olipadaase helps break down accumulated lipids and improves the patient's condition by supplementing the missing enzyme activity.
Clinical studies have shown that Olipadase can significantly reduce hepatosplenomegaly and improve liver and spleen function in patients. In the study, after several months of treatment, the patient's liver and spleen volumes were significantly reduced, and related hematological indicators such as platelet counts were also improved, reducing the risk of thrombocytopenia caused by hypersplenism.
The lungs are one of the important organsASMD affected. Olipada enzyme treatment can effectively improve patients' lung function, increase lung capacity and gas exchange capacity, reduce dyspnea and lung lesions, and improve quality of life.
After treatment with Olipadase, the level of abnormally accumulated lipids in the patient's body was significantly reduced, and related biochemical indicators were improved, indicating that the drug has a positive effect in restoring metabolic balance in the body.
Olipadase was generally well tolerated. Although some patients may experience infusion-related reactions, such as fever, chills, allergic reactions, etc., these adverse reactions can usually be effectively controlled through reasonable dose escalation plans and clinical monitoring. Long-term follow-up shows that patients can maintain clinical benefit with continued use of olipadase.
After patients receive Olipadase treatment, clinical symptoms such as fatigue and dyspnea are relieved, and physical functions and mobility are improved, thereby significantly improving the quality of life.
Reference materials:https://www.xenpozyme.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)